Case reportPublished 27 Aug 2022
Necrotizing Fasciitis Complicating Treatment Of Uterine Carcinosarcoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Patients with advanced or recurrent endometrial cancer have limited options once the disease progresses following chemotherapy. The combination of checkpoint inhibitors and tyrosine kinase inhibitors has recently been approved but has the potential for significant morbidity. Case Report: We report a case of a patient who developed necrotizing fasciitis while receiving pembrolizumab and lenvatinib as therapy for metastatic uterine carcinosarcoma. Management required four separate surgeries and prolonged hospitalization. Conclusion: A literature review found no previous reports of this complication with endometrial carcinomas. The purpose of this report is to raise awareness of the possibility of necrotizing fasciitis in relation to these drugs.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Oncology: Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Kerry J. Rodabaugh”
- BylineArticles whose byline prints “Rebecca Anderson”
